[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"outcomes\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:outcomes":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,43,78,99,129],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100466935","anatomy-based-fitting-in-cochear-implant-users-100466935",false,"NCT05360212","Anatomy-based Fitting in Cochear Implant Users","Anatomy-based Fitting in Unexperienced Cochlear Implant Users. Programación Basada en la anatomía en Usuarios Nuevos de Implante Coclear.","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Post-lingual onset of severe to profound sensory-neural hearing loss in the implanted ear(s)\n* Post-OP CT scan of the CI electrode available\n* Subject implanted with MED-EL cochlear implant(s)\n* Subjects received a Flex28 or FlexSoft electrode\n* Subject planned to receive a SONNET 2 \u002FRONDO3 audio processor on the newly implanted side\n* Audio processor not yet activated on the newly implanted side\n* The most apical active electrode contact has to be inserted at least 450°\n* Minimum of 10 active channels can be activated\n* Fluent in Spanish\n* Signed and dated ICF before the start of any study-specific procedure\n\nSpecific inclusion criteria for the possible study groups • Bilateral CI users: Bilateral CI implantation SONNET 2\u002FRONDO3 audio processor on the first ear implanted\n\n* 40% speech recognition a monosyllabic word Test in quiet at 65 dB SPL (last time tested) on the already implanted side\n* 40% speech recognition in a sentence test in noise (10 dB SNR) on the already implanted side First activation of the already implanted side between 3 and 12 months prior to study inclusion\n\n  • Unilateral CI users: Unilateral CI implantation CI user with contralateral hearing ≥ 60 dB (PTA measured at 500, 1000, 2000, and 4000 Hz)\n\n  • SSD CI users: Unilateral CI implantation CI user with contralateral hearing ≤30 dB (PTA measured at 500, 1000, 2000, and 4000 Hz) Interaural threshold gap ≥40 dB\n\n  • Bimodal CI users: Unilateral CI implantation Contralateral ear adequately fitted with a hearing aid CI user with contralateral hearing ≥30 dB (PTA measured at 500, 1000, 2000, and 4000 Hz) CI user with contralateral hearing ≤55 dB (PTA measured at 500, 1000, 2000, and 4000 Hz) Interaural threshold gap ≥15 dB\n\nExclusion Criteria:\n\n* Lack of compliance with any inclusion criteria\n* EAS user (user of an EAS audio processor)\n* Implanted with C40+, C40X and C40C\n* Implanted with an ABI or Split electrode array\n* Known allergic reactions to components of the investigational medical device\n* Anything that, in the opinion of the Investigator, would place the subject at increased risk or preclude the subject's full compliance with or completion of the study",true,"ALL","18 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","In this study, the performance with the CI is investigated over time in three groups of freshly implanted CI users. Both the standard frequency-band distribution and anatomy-based fitting will be used to compare outcomes.",[27,28,29],"Cochlear Implant","Outcomes","Quality of Life","RECRUITING","2025-08-06",{"date":33,"type":34},"2025-08-12","ACTUAL",{"date":36,"type":34},"2022-03-11",{"date":38,"type":21},"2026-12-31",{"name":40,"class":41},"Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":62,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":42},"100417430","multicomponent-prehabilitation-and-outcomes-in-elderly-patients-with-frailty-100417430","NCT04715581","Multicomponent Prehabilitation and Outcomes in Elderly Patients With Frailty","Effect of Multicomponent Prehabilitation on Early and Long-term Outcomes in Elderly Patients With Frailty After Digestive Surgery for Cancer: A Randomized-controlled Study","Inclusion criteria:\n\n1. Age ≥65 years but \\\u003C90 years;\n2. Scheduled to undergo major surgery for digestive cancer with an expected duration of 2 hours and longer, including cancers of esophagus, stomach, small intestine, colon, rectum, pancreas, liver, and biliary tract;\n3. Clinical Frailty Scale ≥5;\n4. Provide written informed consent.\n\nExclusion Criteria:\n\n1. Preoperative history of schizophrenia, epilepsy, Parkinsonism, or myasthenia gravis;\n2. Inability to communicate due to coma, profound dementia, or language barrier;\n3. Inability to participate in preoperative rehabilitation due to paralysis, fracture or other movement disorder;\n4. Inability to take oral diet due to preoperative gastrointestinal disease or other disease;\n5. Severe heart dysfunction (left ventricular ejection fraction \\\u003C30% or New York Heart Association classification IV), severe hepatic dysfunction (Child-Pugh class C), severe renal dysfunction (undergoing dialysis before surgery), or American Society of Anesthesiologists classification of grade 4 or higher;\n6. Other reasons that are considered unsuitable for study participation.","65 Years","89 Years",{"count":53,"type":21},540,[24],"The study is designed to investigate the effect of a multicomponent prehabilitation pathway on early and long-term outcomes in elderly patients with frailty recovering from surgery for digestive cancer.",[57,58,59,60,61,28],"Old Age; Debility","Digestive Cancer","Surgery","Preoperative Rehabilitation","Nutrition Therapy",[63,64,65,66,67,68],"older patients","frailty","digestive cancer","prehabilitation","nutrition therapy","outcomes","2025-07-29",{"date":71,"type":34},"2025-07-31",{"date":73,"type":34},"2021-11-25",{"date":75,"type":21},"2028-12",{"name":77,"class":41},"Peking University First Hospital",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":95,"leadSponsor":97,"locationsCount":42},"100597636","affection-of-symptoms-duration-on-outcomes-of-lumbar-spine-surgery-100597636","NCT07061067","Affection of Symptoms Duration on Outcomes of Lumbar Spine Surgery","Inclusion Criteria:\n\n* Age ≥18 years old.\n* Both sexes.\n* Patients undergoing lumbar spine surgery\n* Presenting symptoms include lumbar back pain, lumbar radiculopathy, neurogenic claudication, lower-extremity weakness, bowel or bladder symptoms, and duration of symptoms.\n\nExclusion Criteria:\n\n* Previous spinal surgery.\n* Vascular claudication.\n* Comorbid pathology affecting walking ability.\n* Severe comorbidities that may impact surgery outcomes (e.g., uncontrolled diabetes, cardiovascular disease).\n* Bony metastases.\n* Unfit for general anaesthesia.",{"count":85,"type":21},60,"OBSERVATIONAL","This study aims to evaluate the affection of symptoms duration on outcomes of lumbar spine surgery.",[89,28,90],"Symptom Duration","Lumbar Spine Surgery","2025-07-19",{"date":93,"type":34},"2025-07-22",{"date":91,"type":34},{"date":96,"type":21},"2026-01-01",{"name":98,"class":41},"Kafrelsheikh University",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":107,"targetDuration":109,"studyType":86,"phases":4,"briefSummary":110,"conditions":111,"keywords":114,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":128},"100482563","surgical-registry-of-endocarditis-europe-100482563","NCT05563662","SURgical Registry of ENDocarditis EuRope","SURgical Registry of Infective ENDocarditis in EuRope - SURRENDER","SURRENDER","Inclusion Criteria:\n\n* Patients with infective endocarditis (according to DUKE criteria) undergoing cardiac surgery\n* Age ≥18 years\n* Written informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Missing declaration of consent\n* Current participation in another interventional trial",{"count":108,"type":21},10000,"5 Years","This is a prospective, multicentric, european registry of patients with infective endocarditis undergoing cardiac surgery. Patient demographics, clinical data and laboratory values will be collected, as well as treatment outcomes at day 30, day 90 and 1-5 years after the intervention.",[112,113,28],"Infective Endocarditis","Cardiac Surgery",[112,115,116,59,117],"Registry","European","Prognosis","NOT_YET_RECRUITING","2023-05-09",{"date":121,"type":34},"2023-05-10",{"date":123,"type":21},"2023-09",{"date":125,"type":21},"2033-04",{"name":127,"class":41},"University Hospital, Essen",2,{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":17,"minAge":137,"maxAge":138,"enrollmentInfo":139,"targetDuration":141,"studyType":86,"phases":4,"briefSummary":142,"conditions":143,"keywords":148,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":161},"100478155","european-multicentre-registry-of-percutaneous-paravalvular-leak-closure-100478155","NCT05506293","European Multicentre Registry of Percutaneous Paravalvular Leak Closure","European Multicentre Registry of Percutaneous Paravalvular Leak Closure - EuroPVL Study","EuroPVL","Inclusion Criteria:\n\n* ≥16 years of age No opposition from the patient or the representative of the parental authority if the patient is a minor Patient referred for a percutaneous paraprosthetic leak closure procedure\n\nExclusion Criteria:\n\n* \\\u003C 16 years old Refusal of the patient to participate in the observatory or of the legal representative if the patient is a minor","16 Years","110 Years",{"count":140,"type":21},400,"2 Years","Paraprosthetic cardiac valve leaks are a progressive complication after after surgical or percutaneous heart valve replacement. These leaks can lead to heart failure and\u002For life-threatening hemolysis.\n\nPercutaneous closure of para-prosthetic leaks has been developed as an alternative to surgery in high-risk patients. These procedures remain technically challenging with a significant risk of failure and complications, but this risk is improved since the development of dedicated prostheses and the increased experience of the operators. The data in the literature concerning percutaneous leak closure remain limited and disparate and mostly retrospective.The impact of the procedures on the quality of life of patients is not known. Beyond the technical aspects and the follow-up of major cardiovascular events, investigators also wonder what is the impact of these procedures on the quality of life of patients. Investigators hypothesize that even a partial reduction in paraprosthetic leakage may be associated with an improvement in quality of life through reduction of transfusion needs and\u002For reduction of dyspnea. A prospective study is warranted to assess the technical and clinical and clinical results of these procedures, together with the evaluation of the the possible benefit on the quality of life of the patients.",[144,145,146,147,29,28],"Cardiac Valve Disease","Paravalvular Aortic Regurgitation","Paravalvular Mitral Regurgitation","Paravalvular Leak",[149,150,151,68],"paravalvular leak","percutaneous intervention","quality of life","2022-08-16",{"date":154,"type":34},"2022-08-18",{"date":156,"type":34},"2020-01-01",{"date":158,"type":21},"2026-07-01",{"name":160,"class":41},"Centre Chirurgical Marie Lannelongue",33]